Skystar Bio-Pharmaceutical Company news

   Watch this stock
Showing stories 1 - 10 of about 72   

Articles published

SKBI 3.14 0.00 (0.00%)
price chart
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non ...
XI'AN, CHINA, May 22, 2015 (Marketwired via COMTEX) -- Skystar Bio-Pharmaceutical Company SKBI, +2.95% a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the ...
Skystar Bio-Pharmaceutical Company Downgraded to Hold at TheStreet (SKBI)
In other Skystar Bio-Pharmaceutical Company news, major shareholder John M. Gregory acquired 50,000 shares of the company's stock on the open market in a transaction dated Wednesday, May 6th.
Skystar Bio-Pharmaceutical Company Downgraded by TheStreet to "Hold ...  WKRB News
The major shareholder of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI ...
John Gregory is the major shareholder of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) 3.14 +0.09 2.95% . He lately purchased 35,000 shares in the company with the transaction value amounting to approx.
Skystar Bio-Pharmaceutical Company major shareholder John M. Gregory ...  Mideast Time
Skystar Bio-Pharmaceutical Company Stock Upgraded (SKBI)
NEW YORK ( TheStreet) -- Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI) has been upgraded by TheStreet Ratings from sell to hold.
Related articles »  
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI)'s major shareholder ...
In a document that's submitted to the U.S. SEC, it was revealed that the major shareholder of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) 3.14 +0.09 2.95% John Gregory, an insider in focus, made purchase via broker for 38,730 shares of the ...
Skystar Bio-Pharmaceutical Company major shareholder Acquires $173500.00 ...
Skystar Bio-Pharmaceutical Company logo Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) major shareholder John M. Gregory purchased 50,000 shares of the stock in a transaction that occurred on Wednesday, May 6th.
Update: Skystar Bio-Pharmaceutical Company Q3 Earnings - Key Developments ...
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) reported double-digit increases for both revenue and net income for Q3. Revenue increased 14.8% to $18.4 million, while net income increased 32% to $4.9 million or $0.57 per fully diluted share.
Related articles »  
Skystar Bio-Pharmaceutical Company (SKBI) Q3 2014 Results - Earnings Call ...
Greetings and welcome to the Skystar Bio-Pharmaceutical Unaudited Third Quarter Fiscal 2014 Results Conference Call. At this time, all participants are in a listen-only mode.
Related articles »  
Skystar Bio - Pharmaceutical Company (SKBI) Q2 2014 Results - Earnings Call ...
Greetings and welcome to the Skystar Bio-Pharmaceutical Second Quarter Fiscal 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Related articles »  
Skystar Bio-Pharmaceutical Company Downgraded by TheStreet (SKBI)
Skystar Bio-Pharmaceutical Company logo TheStreet lowered shares of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) from a buy rating to a hold rating in a report released on Monday.